Hepatitis B vaccination associated with low response in patients with rheumatic diseases treated with biologics
An erratum to this article was published (RMD Open, 17 Feb 2024 ↗)
Authors' conclusion
HBV vaccination response in patients with rheumatic diseases treated with bDMARDs was poorer than expected.
Study context
- Population
- Patients with inflammatory arthritides treated with biological disease-modifying antirheumatic drugs (bDMARDs) (mostly TNFi), negative for anti-HBs and anti-HBc, never vaccinated for Hepatitis B virus (HBV); Engerix B at 0, 1 and 6 months
- Participants
- 62 vs 38
- Exposure
- Patients with inflammatory arthritides on bDMARDs vs vaccinated healthy controls
- Patientsn = 62
- Controlsn = 38reference
- Outcome
- Vaccination response (anti-HBs ≥10 IU/L) assessed ≥1 month after last dose
- Follow-up
- ≥1 month after last dose
Methodological detailshealthy controls, age-matched controls
- Healthy controls
- Age-matched controls
Main finding
As reported in the abstract
Response to HBV vaccination (anti-HBs ≥10 IU/L)
P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Values | P value |
|---|---|---|
| Response by bDMARD class (subgroup)TNFi vs Non-TNFi | TNFi 37.3% · Non-TNFi 9.1% · Tocilizumab 16.7% | P = 0.07 |
| Response among TNFi agents (subgroup) | Infliximab 18.2% · Etanercept 57.1% |
- Response by bDMARD class (subgroup): TNFi n=51; non-TNFi n=11; tocilizumab n=6 (within non-TNFi)
- Response among TNFi agents (subgroup): range of response rates among TNFi; infliximab n=22, etanercept n=14
Safety
Disease flare, serious adverse events, new immune-related disorders
- No relevant safety issues identified
Original publication
Hepatitis B vaccination associated with low response in patients with rheumatic diseases treated with biologics. RMD Open. Published 6 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →